Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2

Cancer Research

Volumn 74, Issue 17, 2014, Pages 4752-4761

  Lee, Yun Han ^a,b   Seo, Daekwan ^a   Choi, Kyung Ju ^b   Andersen, Jesper B ^a   Won, Min Ah ^b   Kitade, Mitsuteru ^a   Gómez Quiroz, Luis E ^a   Judge, Adam D ^c   Marquardt, Jens U ^a   Raggi, Chiara ^a   Conner, Elizabeth A ^a   MacLachlan, Ian ^c   Factor, Valentina M ^a   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c Tekmira Pharmaceuticals Corporation   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 6; CYCLINE; HDAC2 PROTEIN, HUMAN; HISTONE DEACETYLASE 2; ISOPROTEIN; P27 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; PROTEIN P53;

ANIMAL; APOPTOSIS; CELL CYCLE; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; GLYCOLYSIS; HEPG2 CELL LINE; HUMAN; LIPID METABOLISM; LIPOGENESIS; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MOUSE; PATHOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 6; DISEASE PROGRESSION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HEP G2 CELLS; HISTONE DEACETYLASE 2; HUMANS; LIPID METABOLISM; LIPOGENESIS; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; PPAR GAMMA; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84907053778     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3531     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005;55:74-108.
2. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90.
5. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87.
6. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46.
7. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-604.
8. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25:212-25.
9. Kramer OH. HDAC2: a critical factor in health and disease. Trends Pharmacol Sci 2009;30:647-55.
10. Delcve GP, Khan DH, Davie JR. Targeting class I histone deacetylases in cancer therapy. Expert Opin Ther Targets 2013;17:29-41.
11. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3b activity. Nat Med 2007;13:324-31.
12. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 2013; 7:47-60.
13. Glass E, Viale PH. Histone deacetylase inhibitors: novel agents in cancer treatment. Clin J Oncol Nurs 2013;17:34-40.
14. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villa-nueva A, et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012;56:1343-50.
15. Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012;4:505-24. Review. Erratum in: Future Med Chem 2012; 4:1369-70.
16. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of g-H2AX Foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006;66:11298-304.
17. Bauer S, Hilger RA, Muhlenberg T, Grabellus F, Nagarajah J, Hoiczyk M, et al. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer 2014;110:1155-62.
18. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009;107:600-8.
19. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76.
20. Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, et al. Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res 2010;70: 8264-9.
21. Lee YH, Judge AD, Seo D, Kitade M, Gomez-Quiroz LE, Ishikawa T, et al. Molecular targeting of CSN5: A mechanism of therapeutic response. Oncogene 2011;30:4175-84.
22. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double stranded RNA in Caenor-habditis elegans. Nature 1998;391:806-11.
23. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
24. Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLa-chlan I. A scalable, extrusion free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 2005;22:362-72.
25. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-7.
26. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-4.
27. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009;119:661-73.
28. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404.
29. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007;67:3145-52.
30. Ropero S, Ballestar E, Alaminos M, Arango D, Schwartz S Jr, Esteller M. Transforming pathways unleashed byaHDAC2 mutation in human cancer. Oncogene 2008;27:4008-12.
31. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2005;13:494-504.
32. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response. Nat Biotechnol 2005;23:457-62.
33. Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010; 2:54ra77.
34. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of theSCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 2004;428:190-3.
35. Haberland M, Carrer M, Mokalled MH, Montgomery RL, Olson EN. Redundant control of adipogenesis by histone deacetylases 1 and 2. J Biol Chem 2010;285: 14663-70.
36. Nebbioso A, Dell'Aversana C, Bugge A, Sarno R, Valente S, Rotili D, et al. HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J Mol Endocrinol 2010;45:219-28.
37. Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutr J 2014;13:17.
38. Li P, Wang D, Yao H, Doret P, Hao G, Shen Q, et al. Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 2010;29:3153-62.
39. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009;280:168-76.
40. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther 2006;13:464-77.
41. Hokaiwado N, Takeshita F, Banas A, Ochiya T. RNAi-based drug discovery and its application to therapeutics. IDrugs 2008;11:274-8.
42. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumor-igenesis. Cancer Cell 2004;5: 455-63.
43. Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid RM, et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009;58:1399-1409.
44. Kidani Y, Bensinger SJ. Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol Rev 2012;249:72-83.
45. Zhang F, Kong D, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-g as a therapeutic target for hepatic fibrosis: from bench to bedside. Cell Mol Life Sci 2013;70:259-76.
46. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in nonalcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56:1384-91.
47. Wu CW, Farrell GC, Yu J. Functional role of peroxisome-proliferator-activated receptor g in hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1665-69.